# Section 202: Ipratropium

---

Ipratropium
213
Ipratropium
Mechanism of Action
Inhibits interaction of acetylcholine at receptor sites on the bronchial smooth muscle, thereby resulting in decreased cGMP and bronchodilation
Uses
COPD, Asthma
Contraindications
Hypersensitivity to this product, atropine, bromide, soybean or peanut products
Precautions
Breastfeeding, children <12 yr, angioedema, heart failure, surgery, acute bronchospasm, bladder obstruction, closed-angle glaucoma, prostatic
hypertrophy, urinary retention, pregnancy (B)
Protocol Uses
COPD / Asthma / Sridor – Adult (p35), Hazmat, General – Adult, Trauma (p79), Wheezing / Asthma – Peds (p93)
Side Effects
CNS: Anxiety, dizziness, headache, nervousness
CV: Palpitations
EENT: Dry mouth, blurred vision, nasal congestion
GI: Nausea, vomiting, cramps
Skin: Rash
RESP: Cough, worsening of symptoms, bronchospasms
Pharmacokinetics
15% of dose reaches lower airways. Protein binding <9%, half-life elimination 2 hours
INH – onset 15 minutes, peak 1-2 hours, duration 2-5 hours
Pregnancy Category – B
Interactions
Increase: toxicity—other bronchodilators (INH)
Increase: anticholinergic action—phenothiazines, antihistamines, disopyramide
EMT Considerations
Assess: Palpitations; respiratory status (rate, rhythm, auscultate breath sounds prior to and after administration
Perform/provide: Storage at room temp
Evaluate: Therapeutic response: ability to breathe adequately
Treatment of Overdose
Discontinue product; supportive care
Pharmaceuticals
~ This Space Intentionally Left Blank ~
B EMT
A A-EMT
P Paramedic
M Medical Control
EMR
